CA3000670A1 - Method of treating melanocortin-4 receptor pathway-associated disorders - Google Patents

Method of treating melanocortin-4 receptor pathway-associated disorders Download PDF

Info

Publication number
CA3000670A1
CA3000670A1 CA3000670A CA3000670A CA3000670A1 CA 3000670 A1 CA3000670 A1 CA 3000670A1 CA 3000670 A CA3000670 A CA 3000670A CA 3000670 A CA3000670 A CA 3000670A CA 3000670 A1 CA3000670 A1 CA 3000670A1
Authority
CA
Canada
Prior art keywords
arg
trp
phe
pen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3000670A
Other languages
English (en)
French (fr)
Inventor
Shubh Sharma
Leonardus H.T. Van Der Ploeg
Bart Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhythm Pharmaceuticals Inc
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of CA3000670A1 publication Critical patent/CA3000670A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3000670A 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders Pending CA3000670A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235003P 2015-09-30 2015-09-30
US62/235,003 2015-09-30
PCT/US2016/054455 WO2017059075A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Publications (1)

Publication Number Publication Date
CA3000670A1 true CA3000670A1 (en) 2017-04-06

Family

ID=57138146

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3000670A Pending CA3000670A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders
CA3000673A Pending CA3000673A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders
CA3302750A Pending CA3302750A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3000673A Pending CA3000673A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders
CA3302750A Pending CA3302750A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Country Status (20)

Country Link
US (5) US10960046B2 (enExample)
EP (5) EP4711004A3 (enExample)
JP (8) JP7051106B2 (enExample)
KR (1) KR20180063221A (enExample)
CN (2) CN108601816A (enExample)
AU (6) AU2016330772A1 (enExample)
BR (1) BR112018006674A2 (enExample)
CA (3) CA3000670A1 (enExample)
DK (1) DK3356386T3 (enExample)
ES (1) ES2985734T3 (enExample)
FI (1) FI3356386T3 (enExample)
HK (1) HK1259424A1 (enExample)
IL (3) IL299541A (enExample)
MA (2) MA43040A (enExample)
MX (2) MX2018003983A (enExample)
PL (1) PL3356386T3 (enExample)
PT (1) PT3356386T (enExample)
SG (1) SG10202101510XA (enExample)
WO (2) WO2017059076A1 (enExample)
ZA (1) ZA201802704B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
MX2018003983A (es) * 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
WO2019099735A1 (en) * 2017-11-15 2019-05-23 Rhythm Pharmaceuticals, Inc. Sustained release peptide formulations
CA3090966A1 (en) 2018-02-20 2019-08-29 Charite - Universitatsmedizin Berlin Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
CN108841932B (zh) * 2018-07-13 2021-03-12 东北农业大学 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用
EP4146827A1 (en) * 2020-05-04 2023-03-15 Regeneron Pharmaceuticals, Inc. Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof
JP2023542985A (ja) * 2020-09-24 2023-10-12 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン－４受容体経路関連障害の治療方法
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
KR20250106335A (ko) * 2022-07-12 2025-07-09 리듬 파마슈티컬즈, 인코포레이티드 Mc4r 효능제로 비만을 치료하는 방법
US20260103529A1 (en) 2022-10-18 2026-04-16 Confo Therapeutics N.V. Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders
KR20250127061A (ko) * 2022-11-18 2025-08-26 리듬 파마슈티컬즈, 인코포레이티드 Mc4r 작용제를 이용한 비만 치료 방법
WO2024155828A1 (en) * 2023-01-18 2024-07-25 Loma Linda University Health Uses of aminopyridines in the management of weight and satiety
CN117143183B (zh) * 2023-08-25 2024-08-16 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用
WO2026022136A1 (en) * 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1860697A (en) 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
WO2004076690A2 (de) 2003-02-19 2004-09-10 Universit�T Duisburg-Essen Verwendung einer genveränderung im humanen gnas-gen zur vorhersage von erkrankungsrisiken, krankheitsverläufen und zur vorhersage des ansprechens auf krankheitstherapien
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
EA200600055A1 (ru) 2003-06-19 2006-08-25 Эли Лилли Энд Компани Агонисты рецептора меланокортина 4 (мк4 ) и их применение
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
EP1915168A4 (en) 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
ES2663916T3 (es) * 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US20100016238A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Peptides for Use in the Treatment of Obesity
US20100056433A1 (en) 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
JP2010516654A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
EP2300036B1 (en) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
AR072072A1 (es) 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
JP5530438B2 (ja) 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
WO2010025142A1 (en) 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
EP2370104A1 (en) 2008-11-25 2011-10-05 Novo Nordisk A/S Peptides for treatment of obesity
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
BRPI1009644B1 (pt) 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
MX2012001513A (es) 2009-08-05 2012-05-22 Ipsen Pharma Sas Uso de melanocortinas para tratar la dislipidemia.
ES2624451T3 (es) 2009-08-31 2017-07-14 Tensive Controls, Inc. Ligandos de melanocortina estabilizados
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
JP6622690B2 (ja) * 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
MX2018003983A (es) * 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.

Also Published As

Publication number Publication date
JP2021102650A (ja) 2021-07-15
JP2025019234A (ja) 2025-02-06
AU2021201448A1 (en) 2021-03-25
KR20180063221A (ko) 2018-06-11
JP7051106B2 (ja) 2022-04-11
US20250195606A1 (en) 2025-06-19
JP2018531937A (ja) 2018-11-01
IL289996B2 (en) 2023-07-01
US20180311309A1 (en) 2018-11-01
JP2021088611A (ja) 2021-06-10
JP2018531938A (ja) 2018-11-01
MA43040A (fr) 2018-08-08
AU2024278597A1 (en) 2025-01-16
EP3355905A1 (en) 2018-08-08
PL3356386T3 (pl) 2024-08-05
MX2018003983A (es) 2018-11-09
EP4029513A1 (en) 2022-07-20
EP4360704A3 (en) 2024-07-24
US10960046B2 (en) 2021-03-30
FI3356386T3 (fi) 2024-05-16
JP2023078335A (ja) 2023-06-06
DK3356386T3 (da) 2024-05-21
IL299541A (en) 2023-02-01
ES2985734T3 (es) 2024-11-07
US20220226425A1 (en) 2022-07-21
EP3356386A1 (en) 2018-08-08
AU2022279420B2 (en) 2024-09-19
WO2017059076A1 (en) 2017-04-06
US12263202B2 (en) 2025-04-01
BR112018006674A2 (en) 2018-10-09
US20180215790A1 (en) 2018-08-02
WO2017059075A1 (en) 2017-04-06
IL289996A (en) 2022-03-01
CN108431023B (zh) 2022-11-04
IL258412A (en) 2018-05-31
JP2026042856A (ja) 2026-03-11
JP2022173426A (ja) 2022-11-18
MA43038A (fr) 2018-08-08
US20210169970A1 (en) 2021-06-10
JP7752373B2 (ja) 2025-10-10
EP4711004A3 (en) 2026-05-27
CN108601816A (zh) 2018-09-28
PT3356386T (pt) 2024-05-17
AU2022279420A1 (en) 2023-01-19
EP4360704A2 (en) 2024-05-01
WO2017059076A8 (en) 2018-04-26
IL258412B2 (en) 2023-06-01
JP6940853B2 (ja) 2021-09-29
EP4711004A2 (en) 2026-03-18
CN108431023A (zh) 2018-08-21
ZA201802704B (en) 2024-08-28
HK1259424A1 (zh) 2019-11-29
CA3302750A1 (en) 2026-05-13
IL289996B1 (en) 2023-03-01
CA3000673A1 (en) 2017-04-06
AU2016330772A1 (en) 2018-04-19
SG10202101510XA (en) 2021-03-30
AU2016330773A1 (en) 2018-04-19
MX2023003358A (es) 2023-03-29
EP3356386B1 (en) 2024-02-14
AU2023229494A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
AU2022279420B2 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
JP2022084844A (ja) ペプチド組成物
EP4216979A1 (en) Methods of treating melanocortin-4 receptor pathway-associated disorders
US20260001915A1 (en) Methods for treating obesity with an mc4r agonist
HK40110854A (en) Method of treating melanocortin-4 receptor pathway-associated disorders
TW201609129A (zh) 用於治療嚴重低血糖症的新穎化合物
EP3752165A1 (en) C/ebp alpha sarna compositions and methods of use
EP4392051A1 (en) Leukocyte-specific cell penetrating molecules
US20220362359A1 (en) Dna vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof
EP3491012A1 (en) Treatment of adult growth hormone deficiency with human growth hormone analogues
WO2026096815A1 (en) Combinations of g-protein coupled hormone receptor modulators and melanocortin 4 receptor agonists and related methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250612

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251023

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251110

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251112

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260618

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260618